Macrophages News and Research RSS Feed - Macrophages News and Research

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found. [More]
New research reveals how a deadly fungus grows and kills immune cells

New research reveals how a deadly fungus grows and kills immune cells

New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections. [More]
Keystone meeting focuses on neuroinflammation, Alzheimer's and other neurodegenerative diseases

Keystone meeting focuses on neuroinflammation, Alzheimer's and other neurodegenerative diseases

As Alzheimer's disease sweeps through the brain, do the brain's immune cells sit idly by and let it happen? Or could they overreact and make the disease worse? [More]
Discovery may lead to new potential treatment for drug-resistant melanoma

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments. [More]
Vitamin D plays major role in preventing diabetes and atherosclerosis

Vitamin D plays major role in preventing diabetes and atherosclerosis

In recent years, a deficiency of vitamin D has been linked to type 2 diabetes and heart disease, two illnesses that commonly occur together and are the most common cause of illness and death in Western countries. Both disorders are rooted in chronic inflammation, which leads to insulin resistance and the buildup of artery-clogging plaque. [More]
New range of purified, soluble immunoreceptors announced by AMSBIO

New range of purified, soluble immunoreceptors announced by AMSBIO

AMSBIO has announced a new range of purified, soluble immunoreceptors involved in key signalling pathways. Together with new indoleamine 2,3-dioxygenase (IDO) assay kits these products that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies that serve as positive controls for inhibition. [More]
Researchers discover new metabolic mechanisms linked to macrophage polarization

Researchers discover new metabolic mechanisms linked to macrophage polarization

A group of researchers from Washington University in St. Louis, Agios Pharmaceuticals and ITMO University has discovered new metabolic mechanisms that regulate macrophage polarization - the unique ability of these immune cells to change their specialization depending on the required task. [More]
New vaccine for post exposure treatment of rabies infection enters human clinical trial

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide. [More]
Salt may help control infection

Salt may help control infection

Researchers at Vanderbilt University and in Germany have found that sodium - salt - accumulates in the skin and tissue in humans and mice to help control infection. [More]

Toning down TREM2 receptor's activity may help prevent neurodegeneration in AD patients

Tackling brain inflammation ameliorates Alzheimer's disease (AD), according to a study published in The Journal of Experimental Medicine. [More]
Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. [More]
Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens. [More]
INRS researchers explore cellular and molecular mechanisms that affect AgNP particles

INRS researchers explore cellular and molecular mechanisms that affect AgNP particles

Whereas resistance to antibiotics complicates certain treatments, antimicrobial silver nanoparticles (AgNP) are gaining popularity for medical use. These particles are toxic for certain bacteria, but what about for humans? Researchers at INRS-Institut Armand-Frappier Research Centre have taken a step toward understanding the cellular and molecular mechanisms that affect these particles. [More]
BHB compound produced during dieting blocks part of immune system involved in inflammatory disorders

BHB compound produced during dieting blocks part of immune system involved in inflammatory disorders

Researchers at Yale School of Medicine have found that a compound produced by the body when dieting or fasting can block a part of the immune system involved in several inflammatory disorders such as type 2 diabetes, atherosclerosis, and Alzheimer's disease. [More]
TUSM researchers awarded $7.4 million to study brain impairment in patients infected with HIV

TUSM researchers awarded $7.4 million to study brain impairment in patients infected with HIV

Researchers at Temple University School of Medicine have been awarded a $7.4 million, five-year grant from the National Institute on Drug Abuse to determine how cocaine and HIV-1 interact to cause brain impairment in patients infected with the human immunodeficiency virus. [More]
Fungal infections rarely develop resistance to combination drug therapy

Fungal infections rarely develop resistance to combination drug therapy

Researchers at the University of Toronto have discovered that Candida albicans -- a leading cause of potentially fatal hospital-acquired infections -- rarely develops resistance to combination drug therapy and, when it becomes resistant, it also becomes less dangerous. [More]
Two new drug compounds appear to be effective in treating endometriosis

Two new drug compounds appear to be effective in treating endometriosis

Two new drug compounds - one of which has already proven useful in a mouse model of multiple sclerosis - appear to be effective in treating endometriosis, a disorder that, like MS, is driven by estrogen and inflammation, scientists report in Science Translational Medicine. [More]
Rice researchers develop new version of hydrogel to promote wound healing

Rice researchers develop new version of hydrogel to promote wound healing

Rice University scientists have found the balance necessary to aid healing with high-tech hydrogel. [More]
PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced. [More]
TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

A team led by scientists at The Scripps Research Institute has identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited neurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that inhibit this enzyme. [More]
Advertisement
Advertisement